Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

By C. Lo, H. Ngan, W. Tso, Chi-leung Liu, C. Lam, R. Poon, S. Fan, J. Wong. Hepatology, 2002

2,596 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/e8e4d4b8773425d31f69ea5a9774e7405c0623f3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Hepatology

Citations in the corpus

A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization (2009, background): “However, TACE continues to be the intraarterial treatment of choice in bridging T2 patients to transplant since it represents the standard of care in treating HCC (31,32).”
AASLD guidelines for the treatment of hepatocellular carcinoma (2018, methodology): “In this analysis, there were nine RCTs identified on the use of TACE (six RCTs) or TAE (three RCTs), published between 1990 and 2005, reporting on a total of 645 patients.((75-84)) Compared with the meta-analysis by Llovet and Bruix, there were two additional RCTs included.”
Hepatocellular carcinoma: a global view (2010, background): “In two randomized, controlled trials, 2-year overall survival was 31–63% in the TACE groups versus 11–27% in the control groups”
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma (2010, background): “In 2002, two prospectively RCTs have demonstrated a significant survival benefit from TACE in selected HCC patients with preserved liver function and adequate performance status [331, 332].”
Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data (2016, background): “The evidence supporting the use of lipiodol TACE in the treatment of HCC comes from two metaanalyses including randomized, controlled trials (RCTs) of arterial embolization or chemoembolization versus conservative management.((7-13)) These metaanalyses identified a distinct survival benefit for lipi”
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy (2023, background): “TACE has been established as the standard of care for the management of intermediate-stage HCC (BCLC B) for the past 20 years based on positive results from two RCTs 212,213 and a subsequent meta-analysis 173 .”
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. (2010, neutral): “1) 12 (19) T1/T2 22 (22) 15 (68) 8 (36) 13.”
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, background): “In 2011, a metaanalysis by Cochrane investigators challenged the efficacy of TACE.518 Several biases contained in this assessment, including the use of trials with inappropriate control arms or target populations leading to poor outcomes, call into question the impact of this investigation.”
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2019, background): “Median OS in BCLC B patients treated with TACE in RCTs has increased from 20 to 26 months because of improved patient selection with acknowledgement that Child-Pugh may not be sufficient to determine patients with expected survival benefit associated with chemoembolization.(146,147) Additionally, te”
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. (2007, background): “In them, the objective response rate ranges between 27% and 55% one month after the procedure [5] and 35% at 6 months [4].”